Format

Send to

Choose Destination
Psychopharmacology (Berl). 2013 Jul;228(1):167-74. doi: 10.1007/s00213-013-3026-8. Epub 2013 Mar 5.

In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia.

Author information

1
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. 318388ep@student.eur.nl

Abstract

RATIONALE:

A deficit in dopamine-1 (D1) receptor function in the prefrontal cortex is suggested to play a role in the cognitive dysfunction observed in patients with schizophrenia. However, the results from positron emission tomography imaging studies of D1 receptor levels in individuals with schizophrenia are mixed.

OBJECTIVES:

The aim of this investigation was to determine whether the in vivo characteristics of the different D1 receptor tracers used in previous reports, [(11)C]SCH23390 and [(11)C]NNC112, may have contributed to these discrepancies reported in the literature.

METHODS:

Eight patients with schizophrenia and 12 healthy control subjects were scanned with both [(11)C]SCH23390 and [(11)C]NNC112.

RESULTS:

[(11)C]SCH23390 and [(11)C]NNC112 binding potentials in both patients and control subjects were compared and no tracer by diagnosis interactions were observed.

CONCLUSIONS:

The results of this study suggest that differences in the binding of [(11)C]SCH23390 and [(11)C]NNC112 observed in previous studies are not due to differences in the in vivo behavior of these tracers.

PMID:
23460265
DOI:
10.1007/s00213-013-3026-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center